<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03033394</url>
  </required_header>
  <id_info>
    <org_study_id>207217</org_study_id>
    <secondary_id>16/LO/2179</secondary_id>
    <secondary_id>33017</secondary_id>
    <nct_id>NCT03033394</nct_id>
  </id_info>
  <brief_title>Beta-lactam Pharmacokinetics in Secondary Care</brief_title>
  <official_title>Defining Adult Beta-lactam Antimicrobial Pharmacokinetics Across the Secondary Care Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently in the UK, TDM is routinely performed for aminoglycosides and glycopeptide&#xD;
      antimicrobial agents, given fears over the narrow therapeutic window of these agents and the&#xD;
      serious adverse events associated with toxicity. However, in critical care the role of TDM&#xD;
      for optimisation of therapy has been demonstrated to help optimise dosing of patients who&#xD;
      tend to have variable pharmacokinetic parameters (J. A. Roberts et al,). This is of growing&#xD;
      importance given that low concentrations of antimicrobial agents, below a micro-organisms&#xD;
      minimum inhibitory concentration (MIC) is believed to be a major driver of AMR. The&#xD;
      investigators set out to explore whether similar observations in PK-PD target variability are&#xD;
      currently being observed across the secondary care setting (outside of critical care) and&#xD;
      whether these appear to be impacting on clinical outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY PARTICIPANTS&#xD;
&#xD;
        -  Participants receiving oral or intravenous therapy will be included in this study.&#xD;
&#xD;
        -  Drug level sampling will be undertaken once the participant is at steady state (after at&#xD;
           least 5 doses have been administered to those on treatment).&#xD;
&#xD;
        -  All patients will be consented using the participation information leaflet and consent&#xD;
           form provided in appendix 1.&#xD;
&#xD;
      DRUG LEVEL SAMPLING&#xD;
&#xD;
        -  Patients will be identified for inclusion, and researchers will discuss inclusion in the&#xD;
           study with the patient and provide clinical information for them to consider.&#xD;
           Individuals will be recruited from all areas of secondary care (including, general&#xD;
           medicine, general surgery, augmented care, and out-patient parenteral antimicrobial&#xD;
           therapy [OPAT]).&#xD;
&#xD;
        -  They will then be consented by researchers after being given at least 24 hours to&#xD;
           consider this information and as long as the patient has expressed interest in&#xD;
           participating to their treating physician.&#xD;
&#xD;
        -  This will include permission for basic, anonymised demographic and clinical data to be&#xD;
           collected related to the patients infection, for which they are receiving antimicrobial&#xD;
           therapy.&#xD;
&#xD;
        -  An extra 3mLs of blood will be collected during the patient's routine daily phlebotomy&#xD;
           round following their consent. They will be enrolled for up to 72 hours or two days of&#xD;
           routine blood tests (whichever is shorter). Up to 10 samples may be taken during the 2&#xD;
           days the patient is enrolled, depending on the number of routine blood tests the patient&#xD;
           receives during that day. No more than 3mLs will be taken per each routine blood sample.&#xD;
           For example, if the individuals will only have routine blood tests taken at 8am on day 1&#xD;
           and day 2. Then only two extra samples will be taken (3mLs on D1 and 3mLs on D2).&#xD;
&#xD;
        -  The time they received their dose of antimicrobials, the length of infusion time (if&#xD;
           available), and time the sample was collected will all be recorded.&#xD;
&#xD;
        -  PK/PD indices for evaluation will be calculated post-hoc during&#xD;
           pharmacokinetic-pharmacodynamic analysis. TDM sampling can occur at any time during the&#xD;
           dosing schedule (in line with routine blood testing).&#xD;
&#xD;
        -  A standard operating procedure for this study can be found in appendix 3.&#xD;
&#xD;
      SAMPLE PREPARATION AND ANALYSIS&#xD;
&#xD;
        -  All blood samples will be allowed to clot and placed on ice. They will be centrifuged at&#xD;
           2,400rpm for 10 minutes. Sera from each sample will be separated into three vials and&#xD;
           stored at -80C.&#xD;
&#xD;
        -  Beta-lactam concentrations will be measured using validated high-performance liquid&#xD;
           chromatography methods.&#xD;
&#xD;
        -  Samples will be stored for up to three years post completion of data collection.&#xD;
&#xD;
             -  Consent will be gained for samples to be used for calibration of electrochemical&#xD;
                sensors in ex-vivo studies. This will be performed within 90 days of the samples&#xD;
                being collected.&#xD;
&#xD;
      PHARMCOKINETIC-PHARMACODYNAMIC MODELLING&#xD;
&#xD;
        -  Data will be anonymised and analysed using Pmetrics in R.&#xD;
&#xD;
        -  Different pharmacokinetic models will be explored using in built statistical analysis&#xD;
           options and visual predictive checks.&#xD;
&#xD;
        -  Pharmacodynamic models will then be incorporated into the model using evidence&#xD;
           identified in the literature for selection of parameters.&#xD;
&#xD;
        -  Monte Carlo simulation will then be used to for simulation of target attainments and&#xD;
           analysis of pharmacodynamic outcomes&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 12, 2017</start_date>
  <completion_date type="Actual">August 1, 2019</completion_date>
  <primary_completion_date type="Actual">August 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fraction of the Dosing Interval Over Which the Concentration of Unbound Drug is Greater Than the Minimum Inhibitory Concentration (fT&gt;MIC)</measure>
    <time_frame>Two to 10 samples taken during the first 120 hours of antimicrobial therapy</time_frame>
    <description>Minimum inhibitory concentration (MIC) is the concentration required to visibly inhibit microbial growth in vitro. The MIC for each drug was defined by non-species related breakpoints provided in EUCAST v11.0. Results are given as a fraction of the dosing interval over which the concentration of the unbound drug is greater than the MIC.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">65</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Beta Lactam Adverse Reaction</condition>
  <condition>Penicillin Allergy</condition>
  <arm_group>
    <arm_group_label>Beta-lactam antibiotic</arm_group_label>
    <description>Observational pharmacokinetic study of non-critical care patients receiving beta-lactam antibiotics for management of infections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta-lactam antibiotic</intervention_name>
    <description>Routine clinical dosing</description>
    <arm_group_label>Beta-lactam antibiotic</arm_group_label>
    <other_name>Penicillin</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants from a non-critical care setting will be recruited after receiving at least 5&#xD;
        doses of target antimicrobial. Participants receiving oral and intravenous therapy will be&#xD;
        eligible.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult subjects over 18 years old&#xD;
&#xD;
          -  Capacity to consent to participation&#xD;
&#xD;
          -  Receiving target antimicrobial (amoxicillin, amoxcillin-clavulanate, cefuroxime,&#xD;
             ceftriaxone, flucloxacillin, meropenem, piperacillin-tazobactam) for at least 5 doses&#xD;
             prior to sampling&#xD;
&#xD;
          -  Appropriate venous access (or for venous access to be gained)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children under 18 years old&#xD;
&#xD;
          -  Lacking capacity or prisoner&#xD;
&#xD;
          -  Anaemia or bleeding disorder, deemed significant by the patients physician&#xD;
&#xD;
          -  Patient's physician deems that they are not suitable for inclusion in the study&#xD;
&#xD;
          -  Patients unlikely to be receiving agent for study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison H Holmes, MD MPH MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Health Protection Research Unit in HCAI &amp; AMR</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 19, 2017</study_first_submitted>
  <study_first_submitted_qc>January 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2017</study_first_posted>
  <results_first_submitted>August 3, 2020</results_first_submitted>
  <results_first_submitted_qc>August 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 30, 2021</results_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Penicillins</keyword>
  <keyword>Drug Monitoring</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Penicillins</mesh_term>
    <mesh_term>Lactams</mesh_term>
    <mesh_term>beta-Lactams</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT03033394/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Beta-lactam Antibiotic</title>
          <description>Observational pharmacokinetic study of non-critical care patients receiving beta-lactam antibiotics for management of infections.&#xD;
Beta-lactam antibiotic: Routine clinical dosing</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Completed Sampling</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Completed Pharmacokinetic Analysis</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Missing data</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Oral dosing not incorporated into pharmacokinetic model</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Level taken at incorrect time</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pharmacokinetic soffware unable to generate predicted values</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Completed Final Analysis</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>1 participant excluded from final analysis as an outlier (&gt;1.5 x interquartile range)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Beta-lactam Antibiotic</title>
          <description>Observational pharmacokinetic study of non-critical care patients receiving beta-lactam antibiotics for management of infections.&#xD;
Beta-lactam antibiotic: Routine clinical dosing</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>6 patients excluded from pharmacokinetic analysis:&#xD;
1 participant missing data&#xD;
3 oral dosing could not be integrated into model&#xD;
1 level taken incorrect time&#xD;
1 model unable to calculate individual predicted value</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>6 patients excluded from pharmacokinetic analysis:&#xD;
1 participant missing data&#xD;
3 oral dosing could not be integrated into model&#xD;
1 level taken incorrect time&#xD;
1 model unable to calculate individual predicted value</population>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="48" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>6 patients excluded from pharmacokinetic analysis:&#xD;
1 participant missing data&#xD;
3 oral dosing could not be integrated into model&#xD;
1 level taken incorrect time&#xD;
1 model unable to calculate individual predicted value</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>6 patients excluded from pharmacokinetic analysis:&#xD;
1 participant missing data&#xD;
3 oral dosing could not be integrated into model&#xD;
1 level taken incorrect time&#xD;
1 model unable to calculate individual predicted value</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fraction of the Dosing Interval Over Which the Concentration of Unbound Drug is Greater Than the Minimum Inhibitory Concentration (fT&gt;MIC)</title>
        <description>Minimum inhibitory concentration (MIC) is the concentration required to visibly inhibit microbial growth in vitro. The MIC for each drug was defined by non-species related breakpoints provided in EUCAST v11.0. Results are given as a fraction of the dosing interval over which the concentration of the unbound drug is greater than the MIC.</description>
        <time_frame>Two to 10 samples taken during the first 120 hours of antimicrobial therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin</title>
            <description>Observational pharmacokinetic study of non-critical care patients receiving beta-lactam antibiotics for management of infections.&#xD;
Beta-lactam antibiotic: Routine clinical dosing</description>
          </group>
          <group group_id="O2">
            <title>Co-amoxiclav</title>
            <description>Observational pharmacokinetic study of non-critical care patients receiving beta-lactam antibiotics for management of infections.&#xD;
Beta-lactam antibiotic: Routine clinical dosing</description>
          </group>
          <group group_id="O3">
            <title>Ceftriaxone</title>
            <description>Observational pharmacokinetic study of non-critical care patients receiving beta-lactam antibiotics for management of infections.&#xD;
Beta-lactam antibiotic: Routine clinical dosing</description>
          </group>
          <group group_id="O4">
            <title>Flucloxacillin</title>
            <description>Observational pharmacokinetic study of non-critical care patients receiving beta-lactam antibiotics for management of infections.&#xD;
Beta-lactam antibiotic: Routine clinical dosing</description>
          </group>
          <group group_id="O5">
            <title>Meropenem</title>
            <description>Observational pharmacokinetic study of non-critical care patients receiving beta-lactam antibiotics for management of infections.&#xD;
Beta-lactam antibiotic: Routine clinical dosing</description>
          </group>
          <group group_id="O6">
            <title>Piperacillin-tazobactam</title>
            <description>Observational pharmacokinetic study of non-critical care patients receiving beta-lactam antibiotics for management of infections.&#xD;
Beta-lactam antibiotic: Routine clinical dosing</description>
          </group>
        </group_list>
        <measure>
          <title>Fraction of the Dosing Interval Over Which the Concentration of Unbound Drug is Greater Than the Minimum Inhibitory Concentration (fT&gt;MIC)</title>
          <description>Minimum inhibitory concentration (MIC) is the concentration required to visibly inhibit microbial growth in vitro. The MIC for each drug was defined by non-species related breakpoints provided in EUCAST v11.0. Results are given as a fraction of the dosing interval over which the concentration of the unbound drug is greater than the MIC.</description>
          <units>unitless</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.457" lower_limit="0.417" upper_limit="0.479"/>
                    <measurement group_id="O2" value="0.429" lower_limit="0.417" upper_limit="0.479"/>
                    <measurement group_id="O3" value="0.747" lower_limit="0.741" upper_limit="1.04"/>
                    <measurement group_id="O4" value="0.417" lower_limit="0.285" upper_limit="0.700"/>
                    <measurement group_id="O5" value="0.333" lower_limit="0.319" upper_limit="0.345"/>
                    <measurement group_id="O6" value="1.63" lower_limit="0.971" upper_limit="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Mortality outcome collected from time target antimicrobial commenced until time target antimicrobial stopped. This was median 9 days (interquartile range 6-13 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Beta-lactam Antibiotic</title>
          <description>Observational pharmacokinetic study of non-critical care patients receiving beta-lactam antibiotics for management of infections.&#xD;
Beta-lactam antibiotic: Routine clinical dosing</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard Wilson</name_or_title>
      <organization>Imperial College London</organization>
      <phone>02033132732</phone>
      <email>richard.wilson@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

